Can a simple drug make CAR-T therapy safer?
NCT ID NCT04148430
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug anakinra can prevent or reduce severe side effects like brain problems and cytokine release syndrome caused by CAR-T cell therapy. About 62 adults with certain B-cell blood cancers who are getting CAR-T treatment will receive anakinra. The goal is to see if this approach makes the therapy safer without affecting its cancer-fighting power.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL ALL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hackensack Meridian Health (Data collection only)
Hackensack, New Jersey, 07601, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- A smarter steroid schedule might tame Chemotherapy's blood sugar spike
- Can donor immune cells be engineered to fight blood cancer?